Pathophysiology of Diabetic Dyslipidemia
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the activation of PPARα reduces small dense LDL particles by (1) producing apo C-III-poor VLDL particles that interacts less well CETP and (2) increasing the formation of large buoyant LDL that has a high affinity to and are easily taken up by LDL receptor.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome (61, 62); these individuals often still have elevated atherogenic lipoproteins such as non-HDL (63), small LDL particles (62, 64), and VLDL (62, 64).”
From Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial (2019) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cholesterol accumulation in the brain, particularly in astrocytes, contributes to this pathological process.”
From Cholesterol-driven pathological astrocytic responses in diabetes-associated cognitive impairment through astrocytic SCAP accumulation and NF-κB–C3 signaling modulation (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Cited by
Items 101–200 of 552
Al-Mhanna, S. B., Ghazali, W. S. W., Batrakoulis, A., Alkhamees, N. H., Drenowatz, C. J., Mohamed, M., Gülü, M., Afolabi, H. A., & Bădicu, G. (2024) · Annals of Applied Sport Science · doi:10.61186/aassjournal.1324 · Cited by 27
Ullah, H., Dacrema, M., Buccato, D. G., Fayed, M. A. A., Lellis, L. F. D., Morone, M. V., Minno, A. D., Baldi, A., & Daglia, M. (2025) · Nutrients · doi:10.3390/nu17050877 · Cited by 21
“Dyslipidemia is strongly associated with obesity and/or T2DM [56,57], and risk factors include smoking, excessive alcohol consumption, obesity, T2DM, and certain medications (e.g., steroids) [58].”
Atageldiyeva, K. K., Nemr, R., Echtay, A. S., Racoubian, E., Sarray, S., & Almawi, W. Y. (2019) · Gene · doi:10.1016/j.gene.2019.144011 · Cited by 21
Liu, Y., Huang, H. Y., Gao, R., & Liu, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00172 · Cited by 23
“Hyperlipidemia is the pathophysiological basis of insulin resistance which can not only exacerbates hyperglycemia but also causes a series of vascular complications in diabetes (Hirano, 2018).”
BackgroundSCUBE2, vascular endothelium, and vascular complications: A systematic review
Ali, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110129 · Cited by 20
Secondary hyperlipidemias: etiology and pathogenesis
Ershova, A. I., Раши, Д. О. А., Иванова, А. А., Aksenova, Y. O., & Meshkov, A. N. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-5-74-81 · Cited by 22
Aamir, K., Khan, H. U., Hossain, C. F., Afrin, M. R., Jusuf, P. R., Waheed, I., Sethi, G., & Arya, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120232 · Cited by 21
Tanaka, M., Sato, T., Endo, K., Inyaku, M., Mori, K., Hosaka, I., Mikami, T., Akiyama, Y., Ohnishi, H., Hanawa, N., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01392-x · Cited by 22
“Among lipid fractions, a high level of sdLDL cholesterol (sdLDL-C) has been reported to be a strong risk factor for atherosclerotic cardiovascular disease [10].”
BackgroundInyaku, M., Tanaka, M., Sato, T., Endo, K., Mori, K., Hosaka, I., Mikami, T., Umetsu, A., Ohnishi, H., Akiyama, Y., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64369 · Cited by 23
“It has been shown that particle size of LDL is particularly important in the pathogenesis of atherosclerosis 7, 8) .”
BackgroundInfluentialBian, X., Ge, Z. K., Chen, X., Zhong, S., Li, L., Xu, W., Li, B., Chen, S., & Lv, G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107665 · Cited by 20
la Cruz, J. L., Trejo‐Hurtado, C. M., Landa‐Moreno, C. I., Peña‐Montes, D. J., Landeros-Páramo, J. L., Cortés‐Rojo, C., Montoya-Pérez, R. D. C., Rosas, G., & Saavedra‐Molina, A. (2023) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-023-09963-w · Cited by 19
“The AgNPs obtained with E. carlinae are also strongly affected by insulin absence (Hirano 2018).”
BackgroundFat mass and obesity-associated gene expression and disease severity in type 2 diabetes mellitus
Gayed, E. M. A. E., Zewain, S. K., Ragheb, A., & El-Naidany, S. S. (2021) · Steroids · doi:10.1016/j.steroids.2021.108897 · Cited by 25
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
“This highly atherogenic lipid dysregulation leads to an increased risk of cardiovascular disease [92].”
Type 3 Diabetes: Linking Insulin Resistance to Cognitive Decline
Chapple, B. E., Bayliss, E., Woodfin, S., Smith, M., Winter, J., & Moore, W. (2025) · Diseases · doi:10.3390/diseases13110359 · Cited by 25
“Diabetic dyslipidemia, a risk factor cardio-vascular disease, is characterized by elevated triglycerides, reduced high-density lipoprotein cholesterol, and slightly increased low-density lipoprotein (LDL) cholesterol [127].”
Hirano, T., Satoh, N., & Ito, Y. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64271 · Cited by 26
“Increased hepatic lipogenesis due to de novo or exogenous fatty acid (FA) fluxes is a common pathophysiological mechanism that promotes Very-low-density lipoprotein (VLDL) production and hepatic steatosis, which leads to develop hypertriglyceridemia and sdLDL generation 10, 11) .”
BackgroundSelf-citationZhou, Q., Wu, Y., & Li, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02605-y · Cited by 20
Shetty, S. S., & Kumari, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-92572-7 · Cited by 20
From worms to humans: Understanding intestinal lipid metabolism via model organisms
Kozan, D. W., Derrick, J. T., Ludington, W. B., & Farber, S. A. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159290 · Cited by 23
Endo, K., Kobayashi, R., Tanaka, M., Tanaka, M., Akiyama, Y., Sato, T., Hosaka, I., Nakata, K., Koyama, M., Ohnishi, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64578 · Cited by 21
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
Atia, T. A., Abdelzaher, M. H., Nassar, S. A., Gafar, H. H., Husseini, M. A. M., Kaabi, A. M. Y., & Sakr, H. I. (2023) · Medicine · doi:10.1097/md.0000000000036322 · Cited by 18
“[16] Furthermore, numerous studies have found a link between diabetes, particularly type 2, and dyslipidemia, [17,18] whereas other studies have found a link between prediabetes and dyslipidemia.”
Aghaei, M., Joukar, F., Hassanipour, S., Ranjbar, Z. A., Naghipour, M., & Mansour‐Ghanaei, F. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01641-1 · Cited by 21
“Studies have consistently demonstrated that individuals with disrupted anthropometric indicators often exhibit elevated FBS levels and, on the other side, diabetes associated with dyslipidemia [13, 14].”
BackgroundGupta, S., Mishra, T., Varshney, S., Kushawaha, V., Khandelwal, N., Rai, P., Garg, R., Dev, K., Gupta, A., Kumar, D., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105776 · Cited by 16
Lusta, K. A., Poznyak, A. V., Sukhorukov, V. N., Eremin, I. I., Nadelyaeva, I. I., & Orekhov, A. N. (2023) · Cells · doi:10.3390/cells12050707 · Cited by 15
“Concordantly, diabetes mellitus exerts an influence on the atherogenic process through its relationship with chronic inflammation [66].”
BackgroundBodaghi, A. B., Ebadi, E., Gholami, M. J., Azizi, R., & Shariati, A. (2023) · Health Science Reports · doi:10.1002/hsr2.1779 · Cited by 24
“39 It's noteworthy to mention that other factors besides HDL contribute to the correlation with IR; for instance, in Caucasians, the TG/HDL ratio is associated with IR.”
BackgroundSaikia, R., Pathak, K., Pramanik, P., Islam, M. A., Karmakar, S., Gogoi, S., Pathak, M. P., Das, D., Sahariah, J. J., Ahmad, M. Z., et al. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100189 · Cited by 21
Large triglyceride-rich lipoproteins from fasting patients with type 2 diabetes activate platelets
Boulet, M. M., Cheillan, D., Filippo, M. D., Buisson, C., Michalski, M., Moulin, P., & Calzada, C. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.03.002 · Cited by 15
“Altogether, our results regarding the 265 presence of large TG-rich particles in fasting T2D patients are in accordance with the 266 literature [24-27].”
ResultEgyptian practical guidance in lipid management 2020
Taha, H., Badran, H. M., Kandil, H., Farag, N. M., Oraby, A., Sharkawy, M. E., Shokry, K., Fawzy, F., Mahrous, H. A., Bahgat, J., et al. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00140-1 · Cited by 15
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
“Under high-fat diet conditions, the excessive intake of energy enhances lipid synthesis, suppresses fatty acid oxidation, and hence promotes renal lipid accumulation (Stadler et al., 2015; Hirano, 2018; Thongnak et al., 2020).”
BackgroundFan, T., Lin, M.-H., & Kim, K. (2023) · Healthcare · doi:10.3390/healthcare11030440 · Cited by 25
“The blood lipid indicators total cholesterol, HDL (high-intensity lipoprotein) cholesterol, and LDL cholesterol, offer better prediction on atherosclerotic cardiovascular disease comorbidity than glycated hemoglobin [12,13].”
BackgroundAgrawal, O. D., & Kulkarni, Y. A. (2023) · Life · doi:10.3390/life13051168 · Cited by 22
Almari, M., Mohammad, A., Abubaker, J. A., & Ziyab, A. H. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s290383 · Cited by 17
Wang, K., Yu, G., Yan, L., Lai, Y., & Zhang, L. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01819-4 · Cited by 20
“This decline slows the clearance rate of circulating TG and VLDL from the bloodstream, ultimately leading to their accumulation and perpetuating hypertriglyceridemia [28].”
Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities
O’Brien, S. T., Neylon, O. M., & O’Brien, T. (2021) · Biomedicines · doi:10.3390/biomedicines9070826 · Cited by 19
“Cholesterol ester transfer protein facilitates the transfer of TGs from triglyceride rich lipoproteins to LDL forming TG-rich LDL which is the preferred substrate of hepatic lipase resulting in increased lipolysis and the formation of sdLDL [33].”
BackgroundKoh, S. M., Chung, S. H., Yum, Y., Park, S.-J., Joo, H. J., Kim, Y., & Kim, E. J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01681-8 · Cited by 17
“These small dense LDL particles are thought to be more atherogenic than other large-buoyant LDL particles [13, 14].”
BackgroundIchikawa, T., Okada, H., Hamaguchi, M., Kurogi, K., Murata, H., Ito, M., & Fukui, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110665 · Cited by 17
Multi-level Analysis of HbA1c in Diagnosis and Prognosis of Diabetic Patients
Mukherjee, S., Ray, S. K., Jadhav, A. A., & Wakode, S. L. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998262501231015051317 · Cited by 22
Chapple, B. E., Woodfin, S., & Moore, W. (2024) · Molecules · doi:10.3390/molecules29040751 · Cited by 15
“This is a common phenomenon among people with type 2 diabetes due to the decreased activity of lipoprotein lipase (LPL), whose major role is to break down blood triacylglycerols [78,79].”
BackgroundSoroush, N., Shahraki, M. N., Jouabadi, S. M., Amiri, M., Aribas, E., Stricker, B. H. C., & Ahmadizar, F. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.04.015 · Cited by 23
Kito, K., Nomoto, H., Sakuma, I., Nakamura, A., Cho, K. Y., Kameda, H., Miya, A., Omori, K., Yanagiya, S., Handa, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110091 · Cited by 16
Yu, X., Lu, J., Li, J., Guan, W. X., Deng, S., Deng, Q., Ye, H., Han, W., Yu, Y., & Zhang, R. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.46821 · Cited by 14
Antihyperlipidemic effect of tyrosol, a phenolic compound in streptozotocin-induced diabetic rats
Ramasamy, C., & Pari, L. (2021) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2021.1926030 · Cited by 14
“A typical pattern of lipid abnormalities, known as diabetic dyslipidemia, includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol (HDL-C) concentration, and a shift toward small dense low-density lipoprotein (LDL) (Hirano 2018).”
BackgroundMetabolic Syndrome and Myocardial Infarction in Women
Μacut, D., Ognjanovic, S. I., Ašanin, M., Krljanać, G., & Milenković, T. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210610114029 · Cited by 19
Xie, J., Pei, X., Zhu, S., Jiang, W., Tang, H., Wu, D., & Xie, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1570239 · Cited by 14
“In addition, numerous studies have demonstrated that waist circumference and waist-to-height ratio outperform BMI in key enzyme in triglyceride metabolism, which is often seen in insulin-resistant individuals (35, 36).”
Alhawari, H. H., Jarrar, Y. B., Abulebdah, D., Abaalkhail, S. J., Alkhalili, M., Alkhalili, S., Alhawari, H. H., Momani, M. S., Obeidat, M. N., Fram, R. K., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091488 · Cited by 12
“The lipid profile is disturbed in DM patients, characterized by elevated levels of triglycerides (TGs) and low-density lipoprotein (LDL), as well as low levels of high-density lipoprotein (HDL) [2].”
BackgroundPotential roles of ellagic acid on metabolic variables in diabetes mellitus: A systematic review
Maleki, V., Abbaszadeh, S., Shoura, S. M. S., Sohrabnavi, A., Sepandi, M., & Taghdir, M. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13729 · Cited by 13
“ties in diabetes mellitus and is directly associated with an increased risk of cardiovascular disease.(37,55) The findings of this systematic”
BackgroundThakur, M., & Tupe, R. S. (2022) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2022.106698 · Cited by 17
Wen, P., Shi, L., Huang, Q., Li, T., Jian, W., Zhao, L., Xu, R., Liu, T., Zhang, B., Wang, H., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.174754 · Cited by 15
Xu, X., Shen, S., Dong, Y., Jiang, L., Wang, J., & Shao, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156385 · Cited by 14
Endo, K., Tanaka, M., Sato, T., Inyaku, M., Nakata, K., Kawaharata, W., Aida, H., Hosaka, I., Akiyama, Y., Hanawa, N., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-24-0770 · Cited by 17
Yahya, R., Jainandunsing, S., Rashid, M., van der Zee, L., Touw, A., de Rooij, F. W. M., Sijbrands, E. J. G., Verhoeven, A. J. M., & Mulder, M. T. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107993 · Cited by 14
Effects of Smoking on Diabetic Nephropathy
Gündoğdu, Y., & Anaforoğlu, İ. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.826383 · Cited by 20
“In 2018, 34.5% of all US adults had prediabetes, the condition that has a high risk of progression to type 2 diabetes mellitus(T2DM) (3).”
BackgroundInfluentialHayashi, T., Ai, M., Goto, S., Nakamura, M., Nagaike, H., Suzuki, R., Abe, Y., Ohta, M., Ito, Y., & Hirano, T. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63383 · Cited by 12
Self-citationShimu, S. J., Mahir, J. U. K., Shakib, F. A. F., Ridoy, A. A., Samir, R. A., Jahan, N., Hasan, M. F., Sazzad, S., Akter, S., Mohiuddin, M. S., et al. (2025) · Medical Sciences · doi:10.3390/medsci13030180 · Cited by 28
“Lipoproteins play a central role in the pathophysiology of insulin resistance and type 2 diabetes [178].”
Update on the impact of lipid and glucose control on diabetic wound healing
Rui, S., Xu, Y., Ji, Z., Li, X., Tao, Z., Luo, W., Yao, Y., Chen, L., & Ma, G. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100408 · Cited by 16
Jibril, M. M., Hamid, A. A., Abas, F., Jeeven, K., Mohammed, A. S., Jaafar, A. H., Dek, M. S. P., & Ramli, N. S. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14058 · Cited by 11
Urinary RBP as an Independent Predictor of Renal Outcome in Diabetic Nephropathy
Cai, F., Zhang, L., Zhao, P., Qiu, F., Mukhtar, A. M., Ma, Y., Chen, J., & Han, F. (2022) · Disease Markers · doi:10.1155/2022/9687868 · Cited by 14
“Increased HDL-C levels may protect patients from cardiovascular disease [26].”
BackgroundFentie, D., & Yibabie, S. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03327-3 · Cited by 11
High-expression of FABP4 in Tubules is a Risk Factor for Poor Prognosis in DKD Patients
Huang, Y. T., Cui, X., Li, Z., Yuan, S., Han, Y., Xu, X., Fu, X., Shi, K., Zhang, Z., Wei, J., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673268265231228125431 · Cited by 11
Tian, S., Guo, T., Qian, F., Qiu, Z., Lu, Q., Li, R., Zhu, K., Li, L., Yu, H., Li, R., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae482 · Cited by 12
Fanlo‐Maresma, M., Esteve-Luque, V., Pintó, X., Padró‐Miquel, A., Corbella, E., & Candás‐Estébanez, B. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000774 · Cited by 11
Izadi, M. S., Eskandari, F., Binayi, F., Salimi, M., Rashidi, F. S., Hedayati, M., Dargahi, L., Ghanbarian, H., & Zardooz, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120924 · Cited by 11
Hu, H., Liang, W., Zhang, Z., Liu, Z., Chu, F., Bao, Y., Ran, J., & Ding, G. (2022) · International Journal of Endocrinology · doi:10.1155/2022/2550744 · Cited by 14
“Dyslipidemia is a metabolic disorder in patients with T2DM that contributes to worsening renal function and proteinuria in DKD [17, 18].”
BackgroundWongmanee, N., Rojanaverawong, W., Boonsong, T., & Hanchang, W. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.08.005 · Cited by 15
“37,38 Defects in insulin secretion and actions cause a decrease in lipoprotein lipase activity which affects the clearance of circulating triglycerides, thus promoting diabetic hypertriglyceridemia.”
BackgroundInfluentialSesamin: A Promising Therapeutic Agent for Ameliorating Symptoms of Diabetes
Huang, S., Chuang, C., Rejano, C. J. F., Tayo, L. L., Hsieh, C.-Y., Huang, S. K., & Tsai, P. (2023) · Molecules · doi:10.3390/molecules28217255 · Cited by 13
“Regardless of insulin resistance or insulin insufficiency, abnormalities in serum lipid levels are frequently observed in diabetic populations [50].”
BackgroundANGPLT3 in cardio-metabolic disorders
Su, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06248-6 · Cited by 11
Park, J., Kim, D. H., Lee, H., Lee, H., Hwang, I., Yoon, Y. E., Park, H. E., Lee, S., Choi, S., Kim, Y.-J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020050 · Cited by 14
Askary, A. E., Gharib, A. F., Almehmadi, M. M., Bakhuraysah, M. M., Hajjiahmed, A. A. A., Al-Hejji, L. I., AlHarthi, M. S., & Shafie, A. (2021) · Open Chemistry · doi:10.1515/chem-2021-0107 · Cited by 15
“Moreover, in diabetic patients, increased LDL-C and decreased HDL-C were observed due to the impairment of lipoprotein metabolism [33].”
BackgroundAmssayef, A., Azzaoui, B. E., Ajebli, M., & Eddouks, M. (2020) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525718666200506100139 · Cited by 13
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
“C are common in patients with diabetes (76).”
Salamat, S., Jahan-Mihan, A., Tabandeh, M. R., & Mansoori, A. (2024) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/178106 · Cited by 10
“Dyslipidaemia, characterized by abnormal serum lipid profile, is a prevalent and significant risk factor for the development of cardiovascular diseases (CVDs) [1] and is closely associated with other metabolic disorders, such as insulin resistance [2].”
BackgroundTie, F., Li, G., Hu, N., Li, J., Wang, Z., & Wang, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110800 · Cited by 10
Hernández-Martín, M., Macho‐González, A., Garcimartín, A., López‐Oliva, M. E., Bocanegra, A., Redondo‐Castillejo, R., Bastida, S., Benedí, J., & Sánchez-Muniz, F. J. (2024) · Food & Function · doi:10.1039/d3fo04103d · Cited by 10
Shingaki, T., Taki, K., Koyanagi, M., Nagaoka, S., Yoshizawa, K., Oki, N., Yoshikawa, A., & Imaoka, T. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1754182 · Cited by 10
Hirano, T., & Ito, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14013 · Cited by 15
Self-citationLiu, X., Yang, W., Liu, J., Huang, X., Fang, Y., Ming, J., Lai, J., Fu, J., Ji, Q., & Wang, L. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13483 · Cited by 8
“34,35 Dyslipide-mia constitutes a major risk factor for the development of CVDs in T2DM patients, with a 1 mmol/L reduction in LDL-C correlating with a 21% reduction in major adverse cardiovascular events.”
Cortisol in metabolic syndrome
Mazgelytė, E., & Karčiauskaitė, D. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.008 · Cited by 24
Nawaz, L., Grieve, D., Muzaffar, H., Iftikhar, A., & Anwar, H. (2024) · Cells · doi:10.3390/cells13141196 · Cited by 12
“Notably, metabolic alterations in circulating lipids pose the highest risk for cardiovascular complications in T2DM [42].”
BackgroundHirano, T. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65164 · Cited by 10
Self-citationChen, X., Zhao, X., Fei, H., Zhang, Y., Pang, J., Liu, Z., Wang, W., Qiao, J., & Cuiping, X. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03038-3 · Cited by 14
“Impaired insulin signaling increases hormone-sensitive lipase activity and augments hepatic VLDL-TG production, driving TG accumulation while simultaneously reducing HDL-C levels through enhanced cholesteryl ester transfer protein activity [46– 48].”
Yang, C., Wang, Z., Zhang, J., Wang, Y., Wang, Z., Wang, H., Wang, Y., & Li, W. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28701 · Cited by 11
“Glucose metabolism disorders are also accompanied by abnormal lipid metabolism.(7) An increase in fat content in the kidneys causes a decrease in the rate of blood flow and accumulation of red blood cells, which reduces kidney perfusion.”
BackgroundEspinoza-Salinas, A., Sotomayor, E. M., Cano-Montoya, J., & González-Jurado, J. A. (2021) · Sustainability · doi:10.3390/su13052439 · Cited by 11
“Numerous studies have established a direct relationship between high values of lipid profile and high levels of plasma insulin measured through Steady-state Plasma Glucose (SSPG) and Quantitative Insulin Sensitivity Check Index (QUICKI), respectively [22,23,45,46].”
BackgroundCheng, P.-C., & Kao, C.-H. (2021) · Endocrine Connections · doi:10.1530/ec-21-0209 · Cited by 10
Cheng, P.-C., & Kao, C.-H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258771 · Cited by 9
“Insulin resistance increases the flux of free fatty acids to the liver, which subsequently produces an excess of very low-density lipoproteins, leading to elevated plasma triglycerides (TG), reduced high-density lipoprotein (HDL) cholesterol, and oxidized low-density lipoprotein (LDL) cholesterol [7].”
BackgroundMujammami, M. H., Aleidi, S. M., Buzatto, A. Z., Alshahrani, A. S., AlMalki, R. H., Benabdelkamel, H., Dubayee, M. A., Li, L., Aljada, A., & Rahman, A. M. A. (2023) · Pharmaceuticals · doi:10.3390/ph16121717 · Cited by 11
“The clinical components of diabetic dyslipidemia involve an increase in the levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) associated with a decrease in the levels of high-density lipoprotein cholesterol (HDL-C) particles [37].”
BackgroundNgema, M., Xulu, N. D., Ngubane, P. S., & Khathi, A. (2024) · Biomedicines · doi:10.3390/biomedicines12061372 · Cited by 10
“…also show that these caloric foods lead to elevated triglycerides and increased release of free fatty acids (FFA) from adipocytes into circulation, which is accompanied by decreased FFA uptake by adipocytes in insulin-dependent tissues, promoting insulin resistance and dyslipidemia [162,163].”
BackgroundJahan, M. S., Haque, M. I., Gautam, M., & Bhuiyan, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39349 · Cited by 12
Khatun, H., Sami, S. A., Mim, F. S., Kumar, P., Islam, A., Rian, I. A. M., Rahman, M. A., Riya, S. I., Lokman, M., Mamun, A., et al. (2025) · Scientifica · doi:10.1155/sci5/6516268 · Cited by 9
“Patients with diabetes mellitus are more susceptible to coronary artery disease owing to the alterations of such parameters [84].”
Ulloque‐Badaracco, J. R., Alarcón‐Braga, E. A., Hernández-Bustamante, E. A., Cabrera-Guzmán, J. C., Dotto-Vasquez, G., Maldonado-Basurto, G. F., Rivera-Cabrera, G., Maita-Arauco, S. H., Horruitiner-Mendoza, A. A., Herrera‐Añazco, P., et al. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251328840 · Cited by 14
“103 Therefore, insulin resistance stimulates the activity of microsomal triglyceride transfer protein and enhances VLDL assembly.”
Lipid Subclasses Differentiate Insulin Resistance by Triglyceride–Glucose Index
Naja, K., Anwardeen, N. R., Albagha, O., & Elrayess, M. A. (2025) · Metabolites · doi:10.3390/metabo15050342 · Cited by 8
“Notably, PC and PE are key components of VLDL, which transports triglycerides, and increased VLDL secretion is a hallmark of IR-associated dyslipidemia [29].”
Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Polo-Barranco, A., Rebolledo-Maldonado, C., Esquiaqui-Rangel, V., Nuñez-Mejia, A., Rambal-Torres, J., Barraza-Ahumada, V., Vargas-Cantillo, S., la Cruz, W. B.-D., Liñán-Martínez, V., Rada-Obeso, V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311427 · Cited by 9
Tarlton, J., Patterson, S., & Graham, A. (2021) · Biology · doi:10.3390/biology10060534 · Cited by 8
“By contrast, elevated plasma concentrations of triacylglycerol-rich lipoproteins reflect increased fatty acid flux from adipose tissue, and are linked with diminution of insulin secretion and induction of insulin resistance in patient cohorts [66].”
BackgroundCheng, M. Z. S. Z., Amin, F. A. Z., Zawawi, N., Chan, K. W., Ismail, N., Ishak, N. A., & Norhaizan, M. E. (2023) · Nutrients · doi:10.3390/nu15132835 · Cited by 11
“Elevated lipid peroxidation and a deficiency in the antioxidant system have been described as oxidative stress indicators [42].”
BackgroundIheagwam, F. N., Iheagwam, O. T., Ogunlana, O. O., & Chinedu, S. N. (2023) · Gene Expression · doi:10.14218/ge.2023.00053 · Cited by 8
Naidoo, K., & Khathi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417609 · Cited by 11
“According to previous studies, increased low-density lipoprotein (LDL) oxidation has been linked to hyperinsulinaemia and impaired glucose tolerance in T2DM [75,76].”
BackgroundHernández-Martín, M., Garcimartín, A., Bocanegra, A., Redondo‐Castillejo, R., Quevedo-Torremocha, C., Macho‐González, A., García-Fernández, R. A., Bastida, S., Benedí, J., Sánchez-Muniz, F. J., et al. (2024) · Foods · doi:10.3390/foods13121794 · Cited by 9
“It is well known that T2DM often coexists with lipid metabolism disorders, developing into severe dyslipidemia [1].”
BackgroundAntidyslipidemic Capacity of Cleome arabica (L.) in Streptozotocin-Induced Diabetic Rats
Amssayef, A., & Eddouks, M. (2021) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525719666210219141618 · Cited by 8
Takechi, R., Sharif, A., Brook, E., Majimbi, M., Chan, D. C., Lam, V., Watts, G. F., & Mamo, J. C. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127481 · Cited by 10
“Dyslipidemia and alterations in lipoprotein metabolism in T2DM have been extensively studied and reviewed (30).”
BackgroundLatha, V. A., Mondu, S. S. D., Eshwar, M. D., Polala, A. R., Nandanavanam, S., & Dodda, S. (2023) · Cureus · doi:10.7759/cureus.35625 · Cited by 18
“The etiology of dyslipidemia appears to be centered on the increased hepatic secretion of large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance [7].”
BackgroundPrognostic Role of Polyvascular Involvement in Patients with Symptomatic Peripheral Artery Disease
Adam, L., Strickler, E., Borozadi, M. K., Bein, S., Bano, A., Muka, T., Drexel, H., & Dopheide, J. F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103410 · Cited by 8
“Thus, the lower LDL-C values might also be interpreted as small-dense LDL-particles (sdLDL-C), a form of LDL-C typical in diabetic patients [26], being even more pro-atherogenic and associated with a higher cardiovascular risk [27].”
Background
Metadata
- Authors
- Hirano, T.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Hirano, Tsutomu
- ORCID
- Hirano, Tsutomu
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-09-01
- Volume
- 25
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6143775
- OpenAlex
- W2820707192
- Cited by
- 552
- References
- 102
- Citations by year
- 2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
- MeSH terms
- Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.